A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

A four-period study to evaluate if the grade glucose infusion procedure will be able to detect an increase in beta-cell glucose sensitivity from exenatide compared to no treatment in healthy subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Exenatide

Criteria

Inclusion Criteria:

• Subject is in good health

• Subject is a non-smoker

Exclusion Criteria:

• Subject has irritable bowel disease

• Subject has a history of cancer

• Subject has a history of hypertension requiring treatment

• Subject is unable to refrain from the use of any prescription or non-prescription medication

• Subject consumes excessive amounts of alcohol or caffeine

• Subject has had major surgery, donated blood or participated in another investigational study in the past 4 weeks